BG505 SOSIP.664 gp140 is a stable, soluble, cleaved HIV envelope trimer.
BG505 SOSIP.664 gp140 is a vaccine candidate indicated to prevent HIV.
The BG505 SOSIP.664 gp140 a vaccine candidate is administered through intramuscular injection.
Clinical Trial NCT03699241: A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
- This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.